Home › Research › Treatments
The views of Alzheimer disease patients and their study partners on proxy consent for clinical trial enrollment
Karlawish J, Kim SY, Knopman D, van Dyck CH, James BD, Marson D.. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2008-03-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Objective To examine the views of Alzheimer disease (AD) patients and their study partners on the ethics of proxy consent for clinical research. Design Cross-sectional interview. Setting At the 13 study sites of a randomized and placebo controlled study of simvastatin for the treatment of AD. Participants Patients with mild-to-moderate AD and their study partners enrolled in an Alzheimer's Disease Cooperative Study trial of simvastatin. Measurements Interviews to assess how participants made the decision to enroll in a randomized controlled trial and their attitudes on proxy consent. Results Study partners of patients judged not capable of providing informed consent reported the same degree of patient involvement in the decision to enroll as the study partners of patients capable of providing informed consent. Most study partners and patients supported proxy consent for this clinical trial and nearly all patients chose their study partner as their proxy. Study partners generally made research enrollment decisions based on what they thought would maximize the patient's well-being as opposed to a substituted judgment. Conclusions Patients and their study partners who were enrolled in a clinical trial supported proxy consent both for themselves and as a matter of policy. Our findings suggest that policies that require substituted judgments may not accord with the views of the people currently participating in AD clinical trials.
What this study adds
Evidence grade: High
This is a trial. This interview study found that patients with Alzheimer's disease and their study partners generally supported proxy consent for clinical trial enrollment. It addresses research enrollment practices and has no implications for treating, curing, or preventing the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Karlawish, J., Kim, S. Y., Knopman, D., van Dyck, C. H., James, B. D., & Marson, D. (2008). The views of Alzheimer disease patients and their study partners on proxy consent for clinical trial enrollment. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. https://doi.org/10.1097/jgp.0b013e318162992d
Vancouver
Karlawish J, Kim SY, Knopman D, van Dyck CH, James BD, Marson D. The views of Alzheimer disease patients and their study partners on proxy consent for clinical trial enrollment. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry. 2008. doi:10.1097/jgp.0b013e318162992d. PMID: 18310554.
BibTeX
@article{karlawish2008-18310554,
author = {Karlawish, J. and Kim, S. Y. and Knopman, D. and van Dyck, C. H. and James, B. D. and Marson, D.},
title = {{The views of Alzheimer disease patients and their study partners on proxy consent for clinical trial enrollment}},
journal = {The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry},
year = {2008},
doi = {10.1097/jgp.0b013e318162992d},
pmid = {18310554},
url = {https://doi.org/10.1097/jgp.0b013e318162992d}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Results Study partners of patients judged not capable of providing informed consent reported the same degree of patient involvement in the decision to enroll as the study partners of patients capable of providing informed consent.
- Our findings suggest that policies that require substituted judgments may not accord with the views of the people currently participating in AD clinical trials.
Why it matters
This interview study found that patients with Alzheimer's disease and their study partners generally supported proxy consent for clinical trial enrollment. It addresses research enrollment practices and has no implications for treating, curing, or preventing the disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designrandomized controlled trial
- Evidence strengthHigh
How this study scored 61/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size and effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry) |
| Journal's citation record | 2 / 4 | American Journal of Geriatric Psychiatry: journal h-index 178 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2008 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (pubmed indexes it as a clinical or observational study) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 4 / 7 | Cited 68 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.4 citations a year over 20 year(s) since 2008 |
| Impact for its field and year | 3 / 6 | Cited 4.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Daniel C. Marson: h-index 78 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Johns Hopkins University: institution h-index 2,306 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 18310554) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 61 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.